Q-omics provides the consensus-scored TSACC profile across patient tissues and cancer cell-line models. TSACC expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSACC is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TSACC RNA expression shows 17,321 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, BLCA, and TGCT as cancer lineages where TSACC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSACC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSACC survival associations across molecular data types. TSACC RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSACC RNA expression–survival associations across cancer types. High TSACC expression shows unfavorable associations in UVM, KIRC, KIRP, MESO, ACC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSACC RNA expression.
This table summarizes TSACC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TSACC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSACC shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, HNSC, LUAD and LIHC. The BLCA box plot shows higher TSACC RNA expression in tumor versus normal tissue (log2 FC = +1.075, t-test p < 0.001).
This table shows molecular features associated with TSACC in patient tissues and cancer cell lines. In patient samples, TSACC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TSACC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
